A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma

Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of aggressive lymphoma. Approximately 60% of fit patients achieve curation with immunochemotherapy, but the remaining patients relapse or have refractory disease, which predicts a short survival. Traditionally, risk stratification in DLBC...

Full description

Bibliographic Details
Main Authors: Adrián Mosquera Orgueira, Jose Ángel Díaz Arías, Rocio Serrano Martín, Victor Portela Piñeiro, Miguel Cid López, Andrés Peleteiro Raíndo, Laura Bao Pérez, Marta Sonia González Pérez, Manuel Mateo Pérez Encinas, Máximo Francisco Fraga Rodríguez, Juan Carlos Vallejo Llamas, José Luis Bello López
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-04-01
Series:Frontiers in Oncology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1157646/full
_version_ 1797837907517505536
author Adrián Mosquera Orgueira
Adrián Mosquera Orgueira
Jose Ángel Díaz Arías
Jose Ángel Díaz Arías
Rocio Serrano Martín
Rocio Serrano Martín
Victor Portela Piñeiro
Victor Portela Piñeiro
Miguel Cid López
Miguel Cid López
Andrés Peleteiro Raíndo
Andrés Peleteiro Raíndo
Laura Bao Pérez
Laura Bao Pérez
Marta Sonia González Pérez
Marta Sonia González Pérez
Manuel Mateo Pérez Encinas
Manuel Mateo Pérez Encinas
Máximo Francisco Fraga Rodríguez
Máximo Francisco Fraga Rodríguez
Juan Carlos Vallejo Llamas
Juan Carlos Vallejo Llamas
José Luis Bello López
José Luis Bello López
author_facet Adrián Mosquera Orgueira
Adrián Mosquera Orgueira
Jose Ángel Díaz Arías
Jose Ángel Díaz Arías
Rocio Serrano Martín
Rocio Serrano Martín
Victor Portela Piñeiro
Victor Portela Piñeiro
Miguel Cid López
Miguel Cid López
Andrés Peleteiro Raíndo
Andrés Peleteiro Raíndo
Laura Bao Pérez
Laura Bao Pérez
Marta Sonia González Pérez
Marta Sonia González Pérez
Manuel Mateo Pérez Encinas
Manuel Mateo Pérez Encinas
Máximo Francisco Fraga Rodríguez
Máximo Francisco Fraga Rodríguez
Juan Carlos Vallejo Llamas
Juan Carlos Vallejo Llamas
José Luis Bello López
José Luis Bello López
author_sort Adrián Mosquera Orgueira
collection DOAJ
description Diffuse Large B-cell Lymphoma (DLBCL) is the most common type of aggressive lymphoma. Approximately 60% of fit patients achieve curation with immunochemotherapy, but the remaining patients relapse or have refractory disease, which predicts a short survival. Traditionally, risk stratification in DLBCL has been based on scores that combine clinical variables. Other methodologies have been developed based on the identification of novel molecular features, such as mutational profiles and gene expression signatures. Recently, we developed the LymForest-25 profile, which provides a personalized survival risk prediction based on the integration of transcriptomic and clinical features using an artificial intelligence system. In the present report, we studied the relationship between the molecular variables included in LymForest-25 in the context of the data released by the REMoDL-B trial, which evaluated the addition of bortezomib to the standard treatment (R-CHOP) in the upfront setting of DLBCL. For this, we retrained the machine learning model of survival on the group of patients treated with R-CHOP (N=469) and then made survival predictions for those patients treated with bortezomib plus R-CHOP (N=459). According to these results, the RB-CHOP scheme achieved a 30% reduction in the risk of progression or death for the 50% of DLBCL patients at higher molecular risk (p-value 0.03), potentially expanding the effectiveness of this treatment to a wider patient population as compared with other previously defined risk groups.
first_indexed 2024-04-09T15:33:16Z
format Article
id doaj.art-617f5691a8e74047b11c6b9eeaa33179
institution Directory Open Access Journal
issn 2234-943X
language English
last_indexed 2024-04-09T15:33:16Z
publishDate 2023-04-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Oncology
spelling doaj.art-617f5691a8e74047b11c6b9eeaa331792023-04-28T05:29:05ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-04-011310.3389/fonc.2023.11576461157646A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphomaAdrián Mosquera Orgueira0Adrián Mosquera Orgueira1Jose Ángel Díaz Arías2Jose Ángel Díaz Arías3Rocio Serrano Martín4Rocio Serrano Martín5Victor Portela Piñeiro6Victor Portela Piñeiro7Miguel Cid López8Miguel Cid López9Andrés Peleteiro Raíndo10Andrés Peleteiro Raíndo11Laura Bao Pérez12Laura Bao Pérez13Marta Sonia González Pérez14Marta Sonia González Pérez15Manuel Mateo Pérez Encinas16Manuel Mateo Pérez Encinas17Máximo Francisco Fraga Rodríguez18Máximo Francisco Fraga Rodríguez19Juan Carlos Vallejo Llamas20Juan Carlos Vallejo Llamas21José Luis Bello López22José Luis Bello López23University Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, SpainHealth Research Institute of Santiago de Compostela, Santiago de Compostela, SpainUniversity Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, SpainHealth Research Institute of Santiago de Compostela, Santiago de Compostela, SpainUniversity Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, SpainHealth Research Institute of Santiago de Compostela, Santiago de Compostela, SpainUniversity Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, SpainHealth Research Institute of Santiago de Compostela, Santiago de Compostela, SpainUniversity Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, SpainHealth Research Institute of Santiago de Compostela, Santiago de Compostela, SpainUniversity Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, SpainHealth Research Institute of Santiago de Compostela, Santiago de Compostela, SpainUniversity Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, SpainHealth Research Institute of Santiago de Compostela, Santiago de Compostela, SpainUniversity Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, SpainHealth Research Institute of Santiago de Compostela, Santiago de Compostela, SpainUniversity Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, SpainHealth Research Institute of Santiago de Compostela, Santiago de Compostela, SpainUniversity Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, SpainHealth Research Institute of Santiago de Compostela, Santiago de Compostela, SpainUniversity Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, SpainHealth Research Institute of Santiago de Compostela, Santiago de Compostela, SpainUniversity Hospital of Santiago de Compostela, Servizo Galego de Saúde (SERGAS), Santiago de Compostela, SpainHealth Research Institute of Santiago de Compostela, Santiago de Compostela, SpainDiffuse Large B-cell Lymphoma (DLBCL) is the most common type of aggressive lymphoma. Approximately 60% of fit patients achieve curation with immunochemotherapy, but the remaining patients relapse or have refractory disease, which predicts a short survival. Traditionally, risk stratification in DLBCL has been based on scores that combine clinical variables. Other methodologies have been developed based on the identification of novel molecular features, such as mutational profiles and gene expression signatures. Recently, we developed the LymForest-25 profile, which provides a personalized survival risk prediction based on the integration of transcriptomic and clinical features using an artificial intelligence system. In the present report, we studied the relationship between the molecular variables included in LymForest-25 in the context of the data released by the REMoDL-B trial, which evaluated the addition of bortezomib to the standard treatment (R-CHOP) in the upfront setting of DLBCL. For this, we retrained the machine learning model of survival on the group of patients treated with R-CHOP (N=469) and then made survival predictions for those patients treated with bortezomib plus R-CHOP (N=459). According to these results, the RB-CHOP scheme achieved a 30% reduction in the risk of progression or death for the 50% of DLBCL patients at higher molecular risk (p-value 0.03), potentially expanding the effectiveness of this treatment to a wider patient population as compared with other previously defined risk groups.https://www.frontiersin.org/articles/10.3389/fonc.2023.1157646/fullmachie learningDLBCL - diffuse large B cell lymphomabortezomibR-CHOPlymphomagenomics
spellingShingle Adrián Mosquera Orgueira
Adrián Mosquera Orgueira
Jose Ángel Díaz Arías
Jose Ángel Díaz Arías
Rocio Serrano Martín
Rocio Serrano Martín
Victor Portela Piñeiro
Victor Portela Piñeiro
Miguel Cid López
Miguel Cid López
Andrés Peleteiro Raíndo
Andrés Peleteiro Raíndo
Laura Bao Pérez
Laura Bao Pérez
Marta Sonia González Pérez
Marta Sonia González Pérez
Manuel Mateo Pérez Encinas
Manuel Mateo Pérez Encinas
Máximo Francisco Fraga Rodríguez
Máximo Francisco Fraga Rodríguez
Juan Carlos Vallejo Llamas
Juan Carlos Vallejo Llamas
José Luis Bello López
José Luis Bello López
A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma
Frontiers in Oncology
machie learning
DLBCL - diffuse large B cell lymphoma
bortezomib
R-CHOP
lymphoma
genomics
title A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma
title_full A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma
title_fullStr A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma
title_full_unstemmed A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma
title_short A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma
title_sort prognostic model based on gene expression parameters predicts a better response to bortezomib containing immunochemotherapy in diffuse large b cell lymphoma
topic machie learning
DLBCL - diffuse large B cell lymphoma
bortezomib
R-CHOP
lymphoma
genomics
url https://www.frontiersin.org/articles/10.3389/fonc.2023.1157646/full
work_keys_str_mv AT adrianmosqueraorgueira aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT adrianmosqueraorgueira aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT joseangeldiazarias aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT joseangeldiazarias aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT rocioserranomartin aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT rocioserranomartin aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT victorportelapineiro aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT victorportelapineiro aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT miguelcidlopez aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT miguelcidlopez aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT andrespeleteiroraindo aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT andrespeleteiroraindo aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT laurabaoperez aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT laurabaoperez aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT martasoniagonzalezperez aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT martasoniagonzalezperez aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT manuelmateoperezencinas aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT manuelmateoperezencinas aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT maximofranciscofragarodriguez aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT maximofranciscofragarodriguez aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT juancarlosvallejollamas aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT juancarlosvallejollamas aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT joseluisbellolopez aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT joseluisbellolopez aprognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT adrianmosqueraorgueira prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT adrianmosqueraorgueira prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT joseangeldiazarias prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT joseangeldiazarias prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT rocioserranomartin prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT rocioserranomartin prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT victorportelapineiro prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT victorportelapineiro prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT miguelcidlopez prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT miguelcidlopez prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT andrespeleteiroraindo prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT andrespeleteiroraindo prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT laurabaoperez prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT laurabaoperez prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT martasoniagonzalezperez prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT martasoniagonzalezperez prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT manuelmateoperezencinas prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT manuelmateoperezencinas prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT maximofranciscofragarodriguez prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT maximofranciscofragarodriguez prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT juancarlosvallejollamas prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT juancarlosvallejollamas prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT joseluisbellolopez prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma
AT joseluisbellolopez prognosticmodelbasedongeneexpressionparameterspredictsabetterresponsetobortezomibcontainingimmunochemotherapyindiffuselargebcelllymphoma